Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.
Related Research units
Abstract
Guidelines recommend that patients with chronic hepatitis C virus (HCV) infection be treated with pegylated interferon and ribavirin for 24, 48, or 72 weeks, based on their virologic response to treatment. We investigated the effects of treating patients for individualized durations.
Bibliographical data
| Original language | English |
|---|---|
| Article number | 5 |
| ISSN | 0016-5085 |
| Publication status | Published - 2011 |
| pubmed | 21784046 |
|---|
